118 related articles for article (PubMed ID: 25740023)
1. A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer.
Groene O; Crosby T; Hardwick RH; Riley S; Greenaway K; Cromwell D
BMJ Open; 2015 Mar; 5(3):e006724. PubMed ID: 25740023
[TBL] [Abstract][Full Text] [Related]
2. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
3. Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer.
Haj Mohammad N; Bernards N; van Putten M; Lemmens VEPP; van Oijen MGH; van Laarhoven HWM
Eur J Cancer; 2017 Jun; 78():28-36. PubMed ID: 28412586
[TBL] [Abstract][Full Text] [Related]
4. Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy.
Lord SR; Hall PS; McShane P; Brown J; Seymour MT
Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):107-13. PubMed ID: 20053542
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.
Petrioli R; Francini E; Roviello F; Marrelli D; Miano ST; Fiaschi AI; Laera L; Bellini MA; Roviello G
J Geriatr Oncol; 2015 Sep; 6(5):380-6. PubMed ID: 26228711
[TBL] [Abstract][Full Text] [Related]
6. Clinical profile of carcinoma stomach at a tertiary care hospital in south India.
Sambasivaiah K; Ibrarullah M; Reddy MK; Reddy PV; Wagholikar G; Jaiman S; Reddy DG; Sarma KV; Hegde GN
Trop Gastroenterol; 2004; 25(1):21-6. PubMed ID: 15303466
[TBL] [Abstract][Full Text] [Related]
7. Low reported taste function is associated with low preference for high protein products in advanced oesophagogastric cancer patients undergoing palliative chemotherapy.
de Vries YC; Boesveldt S; Kampman E; de Graaf C; Winkels RM; van Laarhoven HWM
Clin Nutr; 2019 Feb; 38(1):472-475. PubMed ID: 29254661
[TBL] [Abstract][Full Text] [Related]
8. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N
Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588
[TBL] [Abstract][Full Text] [Related]
9. Factors that affect the duration of the interval between the completion of palliative chemotherapy and death.
Hashimoto K; Yonemori K; Katsumata N; Hotchi M; Kouno T; Shimizu C; Tamura K; Ando M; Takeuchi M; Fujiwara Y
Oncologist; 2009 Jul; 14(7):752-9. PubMed ID: 19596665
[TBL] [Abstract][Full Text] [Related]
10. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.
Crumley AB; Stuart RC; McKernan M; McDonald AC; McMillan DC
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e325-9. PubMed ID: 17645468
[TBL] [Abstract][Full Text] [Related]
11. Variation in palliative care of esophageal cancer in clinical practice: factors associated with treatment decisions.
Opstelten JL; de Wijkerslooth LR; Leenders M; Bac DJ; Brink MA; Loffeld BC; Meijnen-Bult MJ; Minderhoud IM; Verhagen MA; van Oijen MG; Siersema PD
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26919349
[TBL] [Abstract][Full Text] [Related]
12. Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer.
Hingorani M; Dixit S; Johnson M; Plested V; Alty K; Colley P; Beavis AW; Roy R; Maraveyas A
Cancer Res Treat; 2015 Oct; 47(4):706-17. PubMed ID: 25687854
[TBL] [Abstract][Full Text] [Related]
13. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany.
Hofheinz R; Clouth J; Borchardt-Wagner J; Wagner U; Weidling E; Jen MH; Brück P
BMC Cancer; 2016 Dec; 16(1):937. PubMed ID: 27923357
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.
Trumper M; Ross PJ; Cunningham D; Norman AR; Hawkins R; Seymour M; Harper P; Iveson T; Nicolson M; Hickish T
Eur J Cancer; 2006 May; 42(7):827-34. PubMed ID: 16466913
[TBL] [Abstract][Full Text] [Related]
15. Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg.
Haag GM; Byl A; Jäger D; Berger AK
Oncology; 2017; 92(5):291-298. PubMed ID: 28249280
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Ford HE; Marshall A; Bridgewater JA; Janowitz T; Coxon FY; Wadsley J; Mansoor W; Fyfe D; Madhusudan S; Middleton GW; Swinson D; Falk S; Chau I; Cunningham D; Kareclas P; Cook N; Blazeby JM; Dunn JA;
Lancet Oncol; 2014 Jan; 15(1):78-86. PubMed ID: 24332238
[TBL] [Abstract][Full Text] [Related]
17. Effect of age on rates of palliative surgery and chemotherapy use in patients with locally advanced or metastatic gastric cancer.
Nelen SD; van Putten M; Lemmens VEPP; Bosscha K; de Wilt JHW; Verhoeven RHA
Br J Surg; 2017 Dec; 104(13):1837-1846. PubMed ID: 28791679
[TBL] [Abstract][Full Text] [Related]
18. [Indications for chemotherapy in cancers of the esophagus, stomach and pancreas].
Haag C; Ehninger G
Z Gastroenterol; 2002 Apr; 40 Suppl 1():S68-S70. PubMed ID: 11930294
[TBL] [Abstract][Full Text] [Related]
19. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
Stahl M; Maderer A; Lordick F; Mihaljevic AL; Kanzler S; Hoehler T; Thuss-Patience P; Mönig S; Kunzmann V; Schroll S; Sandermann A; Tannapfel A; Meyer HJ; Schuhmacher C; Wilke H; Moehler M;
Eur J Cancer; 2018 Apr; 93():119-126. PubMed ID: 29501977
[TBL] [Abstract][Full Text] [Related]
20. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
